Q-omics provides the consensus-scored CHL1-AS2 profile across patient tissues and cancer cell-line models. CHL1-AS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHL1-AS2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CHL1-AS2 RNA expression shows 10,751 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where CHL1-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHL1-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHL1-AS2 survival associations across molecular data types. CHL1-AS2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHL1-AS2 RNA expression–survival associations across cancer types. High CHL1-AS2 expression shows unfavorable associations in UCEC and THCA, but favorable associations in UVM, ESCA, KIRP and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHL1-AS2 RNA expression.
This table summarizes CHL1-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHL1-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHL1-AS2 shows lower tumor expression in KIRC, COAD, STAD, BRCA, KICH and UCEC. The KIRC box plot shows higher CHL1-AS2 RNA expression in normal versus tumor tissue (log2 FC = −2.036, t-test p < 0.001).
This table shows molecular features associated with CHL1-AS2 in patient tissues and cancer cell lines. In patient samples, CHL1-AS2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
